Business and people highlights from our June issue, including four recent hires and a new facility in the UK.
James Dixon
Bringing with him more than 25 years in the pharmaceutical, biotechnology, and CRO industries, James Dixon has been named Senior Vice President, Quality and Compliance at Cetero Research (Cary, NC).
Richard Farris
Novella Clinical (Research Triangle Park, NC) has made several changes to its team including the appointment of Richard Farris as Senior Director for Project Management and the promotion of Michael Doyle to Global Head of Regulatory Affairs.
Robin Sutherland
Quanticate (Cambridge, MA) has appointed Robin Sutherland as Head of US Operations where she will be responsible for all aspects of business expansion across the United States and Canada.
Dawn Duggan
Dawn Duggan has joined A10 Clinical Solutions (Cary, NC) as Director of Strategic Clinical Solutions where she will be responsible for strategically growing A10’s presence within the northeastern US pharmaceutical and biotechnology hub.
Dr. Reddy’s Laboratories
Pictured above: Y. Hamied, PhD, Chairman of Cipla and Honorary Fellow of Christ’s College, Cambridge, and G. V. Prasad, Vice Chairman and CEO.
Dr. Reddy’s Laboratories has opened a newly expanded Chirotech Technology Center at Cambridge Science Park, UK where Chirotech has been based for the last 20 years. The new 33,000 sq ft facility is purpose built for laboratories and offices and has been fitted to Dr. Reddy’s specific requirements for chemistry, biology and analytics.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.